These results provided evidences that the level of IGFBP-3 is responsible, at least partly, to the enhanced radiosensitivity by Nimotuzumab in ESCC cells with overexpression of EGFR. This evidence concerns the gene EGFR and esophageal squamous cell carcinoma.